These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10934297)

  • 1. Prolongation of the insulinotropic action of glucagon-like peptide 1 by the dimethyl ester of succinic acid in an animal model of type-2 diabetes.
    Garcia-Martinez JA; Cancelas J; Villanueva-Peñacarrillo ML; Valverde I; Malaisse WJ
    Int J Mol Med; 2000 Sep; 6(3):319-21. PubMed ID: 10934297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of the insulinotropic action of GLP-1 by succinic acid dimethyl ester in fed anaesthetized rats.
    García-Martínez JA; Cancelas J; Villanueva-Peñacarrillo ML; Valverde I; Malaisse WJ
    Horm Metab Res; 2000 Aug; 32(8):306-9. PubMed ID: 10983625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression by exendin(9-39)amide of glucagon-like peptide-1 insulinotropic action in rats infused with dimethyl ester of succinic acid.
    Cancelas J; Villanueva-Peñacarrillo ML; Valverde I; Malaisse WJ
    Endocrine; 2001 Aug; 15(3):283-5. PubMed ID: 11762700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation and prolongation of the insulinotropic action of glucagon-like peptide 1 by methyl pyruvate or dimethyl ester of L-glutamic acid in a type 2 diabetes animal model.
    Cancelas J; Villanueva-Peñacarrillo ML; Valverde I; Malaisse WJ
    Endocrine; 2001 Nov; 16(2):113-6. PubMed ID: 11887931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of glucagon-like peptide 1 insulinotropic action by succinic acid dimethyl ester.
    Leclercq-Meyer V; Malaisse WJ
    Life Sci; 1996; 58(14):1195-9. PubMed ID: 8614271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation by glutamic acid dimethyl ester of GLP-1 insulinotropic action in fed anaesthetized rats.
    Cancelas J; Villanueva-Peñacarrillo ML; Valverde I; Malaisse WJ
    Int J Mol Med; 2001 Nov; 8(5):531-2. PubMed ID: 11605022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of GLP-1 insulinotropic action by a nonglucidic nutrient in the pancreas of diabetic GK rats.
    Leclercq-Meyer V; Malaisse WJ
    Biochem Mol Med; 1996 Oct; 59(1):87-90. PubMed ID: 8902200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
    Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
    Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.
    Sandhu H; Wiesenthal SR; MacDonald PE; McCall RH; Tchipashvili V; Rashid S; Satkunarajah M; Irwin DM; Shi ZQ; Brubaker PL; Wheeler MB; Vranic M; Efendic S; Giacca A
    Diabetes; 1999 May; 48(5):1045-53. PubMed ID: 10331409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic and extrapancreatic effects of GLP-1.
    Valverde I; Villanueva-Peñacarrillo ML; Malaisse WJ
    Diabetes Metab; 2002 Dec; 28(6 Pt 2):3S85-9; discussion 3S108-12. PubMed ID: 12688638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic insulinotropic effects of succinic acid dimethyl ester and exendin-4 in anaesthetized rats.
    Cancelas J; Villanueva-Peñacarrillo ML; Valverde I; Malaisse WJ
    Int J Mol Med; 2001 Sep; 8(3):269-71. PubMed ID: 11494054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extrapancreatic action of truncated glucagon-like peptide-I in Otsuka Long-Evans Tokushima Fatty rats, an animal model for non-insulin-dependent diabetes mellitus.
    Mizuno A; Kuwajima M; Ishida K; Noma Y; Murakami T; Tateishi K; Sato I; Shima K
    Metabolism; 1997 Jul; 46(7):745-9. PubMed ID: 9225826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.
    Byrne MM; Gliem K; Wank U; Arnold R; Katschinski M; Polonsky KS; Göke B
    Diabetes; 1998 Aug; 47(8):1259-65. PubMed ID: 9703326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation by methyl pyruvate of GLP-1 insulinotropic action in normal rats.
    Valverde I; Cancelas J; Villanueva-Peñacarrillo ML; Malaisse WJ
    Int J Mol Med; 2001 Jun; 7(6):621-3. PubMed ID: 11351275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.
    Pørksen N; Grøfte B; Nyholm B; Holst JJ; Pincus SM; Veldhuis JD; Schmitz O; Butler PC
    Diabetes; 1998 Jan; 47(1):45-9. PubMed ID: 9421373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
    Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
    Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.
    Gutniak MK; Linde B; Holst JJ; Efendić S
    Diabetes Care; 1994 Sep; 17(9):1039-44. PubMed ID: 7988303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.
    Ritzel R; Schulte M; Pørksen N; Nauck MS; Holst JJ; Juhl C; März W; Schmitz O; Schmiegel WH; Nauck MA
    Diabetes; 2001 Apr; 50(4):776-84. PubMed ID: 11289042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.